MedTrace Logo

A Study of DB-1202 Monotherapy in Advanced Solid Tumors

NCT05785728 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-03-31

No results posted yet for this study

Summary

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1201 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

DB-1202

Administered I.V.

Sponsors & Collaborators

  • DualityBio Inc.

    lead INDUSTRY

Principal Investigators

  • Raymond Zhao · DualityBio Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-28
Primary Completion
2024-02-28
Completion
2024-02-28
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05785728 on ClinicalTrials.gov